LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY

被引：1
|
作者：
Mcinnes, I. [1 ]
Kato, K. [2 ]
Magrey, M. [3 ]
Merola, J. F. [4 ,5 ]
Kishimoto, M. [6 ]
Haaland, D. [7 ,8 ]
Chen, L. [2 ]
Duan, Y. [2 ]
Liu, J. [2 ]
Lippe, R. [9 ]
Wung, P. [2 ]
机构：
[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[2] AbbVie Inc, Immunol, N Chicago, IL USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Harvard Med Sch, Dermatol & Rheumatol, Boston, MA 02115 USA
[6] Kyoto Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan
[7] McMaster Univ, Hamilton, ON, Canada
[8] Waterside Clin, Rheumatol & Clin Immunol Allergy, Barrie, ON, Canada
[9] AbbVie Deutschland GmbH Co KG, Immunol, Wiesbaden, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.799
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0081
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
    McInnes, Iain B.
    Kato, Koji
    Magrey, Marina
    Merola, Joseph F.
    Kishimoto, Mitsumasa
    Haaland, Derek
    Chen, Liang
    Duan, Yuanyuan
    Liu, Jianzhong
    Lippe, Ralph
    Wung, Peter
    RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 275 - 292
  • [2] Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
    Iain B. McInnes
    Koji Kato
    Marina Magrey
    Joseph F. Merola
    Mitsumasa Kishimoto
    Derek Haaland
    Liang Chen
    Yuanyuan Duan
    Jianzhong Liu
    Ralph Lippe
    Peter Wung
    Rheumatology and Therapy, 2023, 10 : 275 - 292
  • [3] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Li, Y.
    Liu, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1137 - 1138
  • [4] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Bu, X.
    Chen, L.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 836 - 837
  • [5] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, Philip J.
    Setty, Arathi
    Papp, Kim
    Van den Bosch, Filip
    Tsuji, Shigeyoshi
    Keiserman, Mauro
    Bu, Xianwei
    Chen, Liang
    Mccaskill, Reva
    Mcdearmon-Blondell, Erin
    Wung, Peter
    Tillett, William
    RHEUMATOLOGY, 2023, 62
  • [6] Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis: Results at 56 Weeks from the SELECT-PsA 1 Study
    McInnes, Iain
    Kato, Koji
    Magrey, Marina
    Merola, Joseph
    Kishimoto, Mitsumasa
    Tena, Cesar Pacheco
    Haaland, Derek
    Chen, Liang
    Duan, Yuanyuan
    Zueger, Patrick
    Liu, Jianzhong
    Lippe, Ralph
    Pangan, Aileen
    Behrens, Frank
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2801 - 2804
  • [7] LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS AT 56 WEEKS FROM THE SELECT-PsA 1 STUDY
    McInnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Tena, C. F. Pacheco
    Haaland, D.
    Chen, L.
    Duan, Y.
    Zueger, P.
    Liu, J.
    Lippe, R.
    Pangan, A.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1288 - 1289
  • [8] SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Carter, K.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1136 - 1137
  • [9] EFFICACY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND A LOW OR HIGH SWOLLEN JOINT COUNT: A SUBGROUP ANALYSIS OF 2 PHASE 3 STUDIES (SELECT-PsA 1 AND SELECT-PsA 2)
    Gossec, L.
    Gladman, D. D.
    Mcdearmon-Blondell, E.
    Sewerin, P.
    Ritchlin, C. T.
    Feng, D.
    Lertratanakul, A.
    Ranza, R.
    Tam, L. S.
    Marchesoni, A.
    Coates, L. C.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1308 - 1309
  • [10] UPADACITINIB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY IN PSORIATIC ARTHRITIS ANALYSES OF THE PHASE 3 SELECT-PsA STUDIES
    Muensterman, E.
    Engelhardt, B.
    Gopalakrishnan, S.
    Anderson, J.
    Mohamed, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 805 - 806
12345